Table 2 Clinical and electrophysiological features in WM subgroups and controls.
| Patients with WM | Control patients | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WM‐S | WM‐MAG | WM‐O‐Dem | WM‐O | |||||||||||||||
| p versus WM‐O | p versus WM‐O | p versus WM‐O | p versus control | |||||||||||||||
| General features | ||||||||||||||||||
| Patient age (years) | 69 (2) | 0.1 | 65 (5) | 0.7 | 66 (4) | 0.5 | 63 (1) | 0.2 | 61 (1) | |||||||||
| Disease duration (years) | 3.0 (0.8) | 0.4 | 6.4 (2.3) | 0.3 | 4.8 (0.3) | 0.5 | 4.3 (0.3) | NA | NA | |||||||||
| IgM levels (g/l) | 18 (5) | 7 | 18 (3) | 7 | 17 (10) | 4 | 21 (1) | NA | NA | |||||||||
| Examination features | ||||||||||||||||||
| Vibration | ||||||||||||||||||
| Toes | 1.8 (0.8) | 0.02 | 2.2 (1.2) | 0.06 | 0.3 (0.3) | 0.005 | 5.1 (0.3) | <0.001 | 7.1 (0.4) | |||||||||
| Fingers | 10.8 (1.4) | 0.8 | 8.8 (1.4) | 0.1 | 9.8 (0.9) | 0.2 | 11.1 (0.3 | <0.001 | 12.6 (0.3) | |||||||||
| Pin loss | 50% | 0.6 | 100% | 0.02 | 75% | 0.2 | 32% | 0.005 | 11% | |||||||||
| DTRs reduced | 33% | 0.6 | 100% | <0.001 | 100% | <0.001 | 16% | 0.3 | 9% | |||||||||
| Proprioception changes | 17% | 0.9 | 40% | 0.1 | 50% | 0.07 | 9% | 0.6 | 5% | |||||||||
| Toe weakness | 0% | 0.9 | 40% | 0.1 | 50% | 0.06 | 8% | 0.5 | 4% | |||||||||
| Tandem gait changes | 17% | 0.8 | 40% | 1.0 | 67% | 0.5 | 29% | 0.001 | 5% | |||||||||
| Sural sensory conductions | ||||||||||||||||||
| SNAP amp (μV) | 3.0 (1.9) | 0.08 | 0.4 (0.4 | 0.004 | 0 | 0.005 | 6.7 (0.5) | <0.001 | 9.2 (0.6) | |||||||||
| SNAP absent | 67% | 0.005 | 80% | 0.001 | 100% | <0.001 | 14% | 0.08 | 3% | |||||||||
| Peroneal motor conductions | ||||||||||||||||||
| CMAP amp (μV) | 2.1 (0.2) | 0.06 | 0.7 (0.2) | 0.001 | 0.3 (0.1) | <0.001 | 3.6 (0.2) | 0.4 | 3.9 (0.2) | |||||||||
| Nerve CV (m/s) | 47 (2) | 0.3 | 34 (3) | <0.001 | 32 (1) | <0.001 | 49 (1) | 0.08 | 51 (1) | |||||||||
| Distal latency (ms) | 5.2 (0.3) | 0.1 | 11.8 (1.4) | <0.001 | 8.6 (1.6) | 0.008 | 5.2 (0.1) | 1.0 | 5.0 (0.1) | |||||||||
Clinical and electrophysiological features in WM subgroups and controls. WM, Waldenström's macroglobulinaemia; WM‐S, patients with WM with serum monoclonal IgM binding to sulphatide at titres >20 000; WM‐MAG, patients with WM with serum monoclonal IgM binding to myelin associated glycoprotein at titres >20 000; WM‐O‐Dem, patients with WM with demyelinating neuropathies but without serum IgM binding to MAG or sulphatide; WM‐O, other patients with WM without serum IgM binding to MAG or sulphatide; IgM levels, g/dl; amp, amplitude; SNAP, sensory nerve action potential; CMAP, compound motor action potential; nerve CV, nerve conduction velocity; NA, not applicable.